Agilent to Acquire Biovectra, a Contract Drug Manufacturer, for $925M
Search our blog for articles and insights right here, just type your interest and dive into a world of knowledge.
Popular articles
Agilent Technologies to Acquire Biovectra for $925 Million
Agilent Technologies has announced plans to purchase Biovectra, a firm specializing in contract drug manufacturing, for $925 million. This strategic acquisition aims to broaden Agilent's service offerings to biotech companies and medical researchers.
Biovectra's Expertise and Services
Biovectra, a Canadian company, provides fill-and-finish services for drug manufacturers and produces active ingredients for complex medications. The company is particularly known for its capabilities in rapidly growing segments like GLP-1 weight loss drugs. This expertise is expected to complement Agilent's existing portfolio, providing a significant boost to its offerings.
Impact on Agilent
Agilent has faced challenges with declining demand for its medical tools and equipment, primarily used in clinical studies. This downturn stems from a funding shortfall among its biotech clients. To finance the Biovectra acquisition, Agilent will utilize a combination of cash reserves and debt financing.
Post-acquisition, Biovectra will be integrated into Agilent's diagnostics and genomics unit. However, the deal is projected to have a dilutive impact of five cents per share on Agilent's profit, one year after the transaction's completion.
Biovectra's Ownership History
Before its acquisition by Agilent, Biovectra was a unit of Mallinckrodt and was later purchased by private equity firm H.I.G. Capital in 2019 for $250 million.
